InvestorsHub Logo

Ruffieruff

04/14/17 11:57 AM

#1935 RE: fishhunter #1934

Fish on paper and science this looks to be solid, but they need a partnership to really make this thing fly. Just did a placement recently. Been in this for a while didn't sell in the last pop

dia76ca

04/14/17 3:52 PM

#1940 RE: fishhunter #1934

Many other treatments are "autologous"...that is they take a tumour sample from the patient...ship it to a central laboratory...test it and treat it in some manner...ship it back to the patient for treatment. This involves a lot of time and additional costs.

HTBX uses an "allogenic" approach where they develop their vaccine from cancer cell lines they choose for overlap with most cancers of that indication. They may target as many as 30 different antigens in the tumour. The cost saving means COGS savings "of two orders of magnitude"...that is instead of costing anywhere from $35,000 to over $100,000 for the vaccine the costs would be only a few thousand dollars...and treatments are not delayed! Here is some of what the company says...

"Clinical and pre-clinical results indicate that the ImPACT Therapy generates a potent anti-tumor immune response that fights targeted tumors and keeps the body tumor-free even when re-challenged with the cancer. This novel live cell vaccine approach is applicable to a wide array of viral infections (including HIV and HCV), parasitic infections (including malaria) and cancer.  Heat’s approach is an off-the-shelf product that does not require invasive surgery or isolation of patient tissues which is required for autologous vaccine technologies."